Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cytokeratin 8 Level in Aqueous Humor, as a Prognostic Factor for Visual and Anatomical Outcomes After Ranibizumab (Lucentis) in Neovascular Age-related Macular Degeneration

NCT02707575 is registered in ClinicalTrials.gov with Gangnam Severance Hospital as lead sponsor.

NCT NCT02707575
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02707575 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Cytokeratin 8 Level in Aqueous Humor, as a Prognostic Factor for Visual and Anatomical Outcomes After Ranibizumab (Lucentis) in Neovascular Age-related Macular Degeneration
Lead sponsor
Gangnam Severance Hospital
Phase
Observational
Overall status
Completed
Start date
April 26, 2016
Completion date
April 23, 2018
Enrollment
58 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

age-related macular degeneration